• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Clinical development of fulvestrant ("Faslodex").

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Howell, Anthony
    Abram, Paul
    Affiliation
    CRUK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. maria.parker@christie-tr.nwest.nhs.uk
    Issue Date
    2005
    
    Metadata
    Show full item record
    Abstract
    This paper outlines the development of fulvestrant, the first in a new class of antioestrogen agents with no agonist effects, to be used for the treatment of hormone receptor-positive advanced breast cancer in postmenopausal women. The role of the oestrogen receptor in breast cancer growth and development and the evolution of pharmacological strategies to manipulate it are also discussed. Preclinical and clinical evidence for the efficacy of fulvestrant are also reviewed, along with the tolerability profile of this agent in relation to other endocrine therapies. Further research will define the role of this exciting new agent in the endocrine treatment of breast cancer.
    Citation
    Clinical development of fulvestrant ("Faslodex"). 2005, 31 Suppl 2:S3-9 Cancer Treat. Rev.
    Journal
    Cancer Treatment Reviews
    URI
    http://hdl.handle.net/10541/74883
    DOI
    10.1016/j.ctrv.2005.08.010
    PubMed ID
    16198055
    Type
    Article
    Language
    en
    ISSN
    0305-7372
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.ctrv.2005.08.010
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • The future of fulvestrant ("Faslodex").
    • Authors: Howell A
    • Issue date: 2005
    • Fulvestrant ('Faslodex'): current and future role in breast cancer management.
    • Authors: Howell A
    • Issue date: 2006 Mar
    • Fulvestrant and the sequential endocrine cascade for advanced breast cancer.
    • Authors: Johnston S
    • Issue date: 2004 Mar
    • Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
    • Authors: Mlineritsch B, Psenak O, Mayer P, Moik M, Namberger K, Hauser-Kronberger C, Greil R
    • Issue date: 2007 Nov
    • Case studies of fulvestrant ("Faslodex") in postmenopausal women with advanced breast cancer.
    • Authors: Abram P, Maass N, Rea D, Simon SD, Steger GG
    • Issue date: 2005
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.